Treatment-Resistant Depression: An Update on Management Strategies-Presentation and Q&A

Video Transcription

Video Summary

In this webinar, Dr. Brayden Kamig discusses treatment-resistant depression and updates on management strategies. She provides an overview of the Clinical and Research Program for Psychosis and the SMI Advisor initiative, which aims to provide evidence-based care for serious mental illnesses. The webinar is eligible for AMA-PRA Category 1 credit for physicians and Nursing Continuing Professional Development Contact Hour. Dr. Kamig talks about the prevalence of depressive disorders and the risk factors associated with them, such as social isolation, educational status, and financial instability. She highlights the high rates of treatment-resistant depression and the associated costs and disability. Dr. Kamig discusses various pharmacological strategies for treatment-resistant depression, including atypical antipsychotics and lithium. She also explores neuromodulation or interventional psychiatry techniques such as electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). Dr. Kamig explains the mechanisms of action and safety considerations for TMS and discusses the use of ketamine as an off-label treatment for treatment-resistant depression. She emphasizes the importance of monitoring and measurement-based care throughout the treatment process. In conclusion, Dr. Kamig provides clinical pearls for evaluating patients with treatment-resistant depression and managing comorbidities such as personality disorders.

Keywords

webinar

treatment-resistant depression

management strategies

evidence-based care

pharmacological strategies

neuromodulation

electroconvulsive therapy

transcranial magnetic stimulation

ketamine

comorbidities